ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

LG Chem and Boryung Pharmaceutical side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

LG ChemBoryung Pharmaceutical
studies on the registry184143
open to participants now1023
phase 3 studies under way31
reach primary completion within a year27
programswith a study of their own in two years1018

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseLG ChemBoryung Pharmaceutical
Phase 1

LG Chem: 2 of its 10 programs at phase 1

  1. Reference Drug (Eutropin, 4 IU/vial)phase 1
  2. Test Drug (Eutropin Catridge, 48IU/Cartridge)phase 1
20%

Boryung Pharmaceutical: 8 of its 18 programs at phase 1

  1. BR1015phase 1
  2. dapagliflozinphase 1
  3. Metforminphase 1
  4. BR2021phase 1
  5. olaparibphase 1

and 3 more — sign in to see them all

44%
Phase 2

LG Chem: 1 of its 10 programs at phase 2

  1. LG00313112phase 2
10%

Boryung Pharmaceutical: 9 of its 18 programs at phase 2

  1. bosmolisibphase 2
  2. BR1400-1phase 2
  3. BR1400-2phase 2
  4. BR1400-3phase 2
  5. BR1400phase 2

and 4 more — sign in to see them all

50%
Phase 3

LG Chem: 4 of its 10 programs at phase 3

  1. rilogrotugphase 3
  2. LBVDphase 3
  3. Metforminphase 3
  4. dapagliflozinphase 3
40%

Boryung Pharmaceutical: 1 of its 18 programs at phase 3

  1. Pioglitazonephase 3
6%
Approved, new studies

LG Chem: 3 of its 10 programs at approved, new studies

  1. Fang Le Shu (Follitrope)approved, new study
  2. Leuprolideapproved, new study
  3. gemigliptinapproved, new study
30%
00%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
LG Chem0 readouts · 0 phase 3············
Boryung Pharmaceutical9 readouts · 0 phase 3···

Boryung Pharmaceutical, Feb ’27: 5 programs whose next study reaches primary completion

  1. BR1400phase 2 · Feb 1 · NCT07373613
  2. BR1400-1phase 2 · Feb 1 · NCT07373613
  3. BR1400-2phase 2 · Feb 1 · NCT07373613
  4. BR1400-3phase 2 · Feb 1 · NCT07373613
  5. BR1400-4phase 2 · Feb 1 · NCT07373613
··

Boryung Pharmaceutical, May ’27: 3 programs whose next study reaches primary completion

  1. BR5402Aphase 2 · May 0 · NCT06821945
  2. BR5402Bphase 2 · May 0 · NCT06821945
  3. BR5402D-1phase 2 · May 0 · NCT06821945
···

Boryung Pharmaceutical, Sep ’27: 1 program whose next study reaches primary completion

  1. bosmolisibphase 2 · Sep 0 · NCT07180771
·
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

LG Chem

New programs 0

None

Reached a new phase 1

Study stopped 0

None

Primary completion later 1

Boryung Pharmaceutical

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 11 in all. A program counts in each condition its studies name most.

ConditionLG ChemBoryung Pharmaceutical
Diabetes Mellitus, Type 2both · compare here

LG Chem in Diabetes Mellitus, Type 2: 3 programs

  1. Metforminphase 3
  2. dapagliflozinphase 3
  3. gemigliptinapproved, new study

Their studies: LG Chem’s studies of Diabetes Mellitus, Type 2 in search

Boryung Pharmaceutical in Diabetes Mellitus, Type 2: 5 programs

  1. Pioglitazonephase 3
  2. dapagliflozinphase 1
  3. Metforminphase 1
  4. BR3006phase 1
  5. BR3409phase 1

Their studies: Boryung Pharmaceutical’s studies of Diabetes Mellitus, Type 2 in search

Diabetes Mellitusboth · compare here

LG Chem in Diabetes Mellitus: 2 programs

  1. Metforminphase 3
  2. dapagliflozinphase 3

Their studies: LG Chem’s studies of Diabetes Mellitus in search

Boryung Pharmaceutical in Diabetes Mellitus: 3 programs

  1. Pioglitazonephase 3
  2. dapagliflozinphase 1
  3. Metforminphase 1

Their studies: Boryung Pharmaceutical’s studies of Diabetes Mellitus in search

Alzheimer Diseaseboth · compare here

LG Chem in Alzheimer Disease: 1 program

  1. Leuprolideapproved, new study

Their studies: LG Chem’s studies of Alzheimer Disease in search

Boryung Pharmaceutical in Alzheimer Disease: 1 program

  1. Pioglitazonephase 3

Their studies: Boryung Pharmaceutical’s studies of Alzheimer Disease in search

Breast Neoplasmsboth · compare here

LG Chem in Breast Neoplasms: 1 program

  1. Leuprolideapproved, new study

Their studies: LG Chem’s studies of Breast Neoplasms in search

Boryung Pharmaceutical in Breast Neoplasms: 1 program

  1. olaparibphase 1

Their studies: Boryung Pharmaceutical’s studies of Breast Neoplasms in search

Diabetes Mellitus, Type 1both · compare here

LG Chem in Diabetes Mellitus, Type 1: 1 program

  1. dapagliflozinphase 3

Their studies: LG Chem’s studies of Diabetes Mellitus, Type 1 in search

Boryung Pharmaceutical in Diabetes Mellitus, Type 1: 1 program

  1. dapagliflozinphase 1

Their studies: Boryung Pharmaceutical’s studies of Diabetes Mellitus, Type 1 in search

Fastingboth · compare here

LG Chem in Fasting: 1 program

  1. Metforminphase 3

Their studies: LG Chem’s studies of Fasting in search

Boryung Pharmaceutical in Fasting: 1 program

  1. Metforminphase 1

Their studies: Boryung Pharmaceutical’s studies of Fasting in search

Heart Failureboth · compare here

LG Chem in Heart Failure: 1 program

  1. dapagliflozinphase 3

Their studies: LG Chem’s studies of Heart Failure in search

Boryung Pharmaceutical in Heart Failure: 1 program

  1. dapagliflozinphase 1

Their studies: Boryung Pharmaceutical’s studies of Heart Failure in search

Obesityboth · compare here

LG Chem in Obesity: 1 program

  1. Metforminphase 3

Their studies: LG Chem’s studies of Obesity in search

Boryung Pharmaceutical in Obesity: 1 program

  1. Metforminphase 1

Their studies: Boryung Pharmaceutical’s studies of Obesity in search

Polycystic Ovary Syndromeboth · compare here

LG Chem in Polycystic Ovary Syndrome: 1 program

  1. Metforminphase 3

Their studies: LG Chem’s studies of Polycystic Ovary Syndrome in search

Boryung Pharmaceutical in Polycystic Ovary Syndrome: 1 program

  1. Metforminphase 1

Their studies: Boryung Pharmaceutical’s studies of Polycystic Ovary Syndrome in search

Prostatic Neoplasmsboth · compare here

LG Chem in Prostatic Neoplasms: 1 program

  1. Leuprolideapproved, new study

Their studies: LG Chem’s studies of Prostatic Neoplasms in search

Boryung Pharmaceutical in Prostatic Neoplasms: 1 program

  1. olaparibphase 1

Their studies: Boryung Pharmaceutical’s studies of Prostatic Neoplasms in search

Renal Insufficiency, Chronicboth · compare here

LG Chem in Renal Insufficiency, Chronic: 1 program

  1. dapagliflozinphase 3

Their studies: LG Chem’s studies of Renal Insufficiency, Chronic in search

Boryung Pharmaceutical in Renal Insufficiency, Chronic: 1 program

  1. dapagliflozinphase 1

Their studies: Boryung Pharmaceutical’s studies of Renal Insufficiency, Chronic in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

TargetLG ChemBoryung Pharmaceutical
COXFA4MetforminruleMetforminrule
COXFA4L2MetforminruleMetforminrule
GPD2MetforminruleMetforminrule
MT-ND1MetforminruleMetforminrule
MT-ND2MetforminruleMetforminrule
MT-ND3MetforminruleMetforminrule
MT-ND4MetforminruleMetforminrule
MT-ND4LMetforminruleMetforminrule
MT-ND5MetforminruleMetforminrule
MT-ND6MetforminruleMetforminrule
NDUFA1MetforminruleMetforminrule
NDUFA10MetforminruleMetforminrule
NDUFA11MetforminruleMetforminrule
NDUFA12MetforminruleMetforminrule
NDUFA13MetforminruleMetforminrule
NDUFA2MetforminruleMetforminrule
NDUFA3MetforminruleMetforminrule
NDUFA5MetforminruleMetforminrule
NDUFA6MetforminruleMetforminrule
NDUFA7MetforminruleMetforminrule
NDUFA8MetforminruleMetforminrule
NDUFA9MetforminruleMetforminrule
NDUFAB1MetforminruleMetforminrule
NDUFAF1MetforminruleMetforminrule
NDUFAF2MetforminruleMetforminrule
NDUFAF3MetforminruleMetforminrule
NDUFAF4MetforminruleMetforminrule
NDUFB1MetforminruleMetforminrule
NDUFB10MetforminruleMetforminrule
NDUFB11MetforminruleMetforminrule
NDUFB2MetforminruleMetforminrule
NDUFB3MetforminruleMetforminrule
NDUFB4MetforminruleMetforminrule
NDUFB5MetforminruleMetforminrule
NDUFB6MetforminruleMetforminrule
NDUFB7MetforminruleMetforminrule
NDUFB8MetforminruleMetforminrule
NDUFB9MetforminruleMetforminrule
NDUFC1MetforminruleMetforminrule
NDUFC2MetforminruleMetforminrule
NDUFS1MetforminruleMetforminrule
NDUFS2MetforminruleMetforminrule
NDUFS3MetforminruleMetforminrule
NDUFS4MetforminruleMetforminrule
NDUFS5MetforminruleMetforminrule
NDUFS6MetforminruleMetforminrule
NDUFS7MetforminruleMetforminrule
NDUFS8MetforminruleMetforminrule
NDUFV1MetforminruleMetforminrule
NDUFV2MetforminruleMetforminrule
NDUFV3MetforminruleMetforminrule
SLC5A2dapagliflozindapagliflozin
A target, or a pathogen for a vaccine, known for: LG Chem 5 of 10 · Boryung Pharmaceutical 5 of 18 programs (8 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.